Charles River Laboratories International Inc. (CRL) carries a Roarable Rating of C+ (Hold) with 67/100 RQD Confidence. The underlying business is intact, so current owners don’t need to panic-sell—but mixed big-money flow or rich pricing means new buyers can afford to wait for either a pullback or a B-or-higher upgrade.
Charles River Laboratories International Inc. (CRL) advanced +0.57% to $376.10 as options desks priced 58% call premium vs. 42% put protection around the $369 max-pain magnet. Solid 41% profit margin (0% return on capital), mixed timing at current multiples—hold if owned, no rush to chase.
Charles River Laboratories International has become a talking point after a sharp multi‑year rally, which naturally raises a harder question for you as an investor: Is the current share price still grounded in the cash f
Charles River Laboratories International (NYSE:CRL) agreed to deploy its Virtual Control Group database for Ipsen to support toxicology studies and reduce animal use. The Ipsen collaboration uses AI powered analytics and
Labcorp Holdings (NYSE: LH) partnered with Waters Corporation to deploy the BD Onclarity HPV Assay across its national laboratory network. The BD Onclarity HPV Assay rollout is designed to broaden access to advanced cerv
Solventum (SOLV) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Ariel Investments, an investment management company, released its “Ariel Appreciation Fund” Q3 2026 investor letter. A copy of the letter can be downloaded here. Copy main article 1st para. The Fund faced a challenging t
Outsourcing in vivo studies cuts costs and timelines, while AI, advanced imaging and genomics sharpen results. Toxicology and oncology lead, with emerging markets offering cost advantages.Dublin, Oct. 28, 2026 (GLOBE NEW
Charles River (CRL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Ariel Appreciation Fund discusses Q3 2026 performance and portfolio adjustments including spin-offs. Read the full analysis for more details.
Madison Investments, an investment advisor, released its “Madison Small Cap Fund” Q3 2026 investor letter. A copy of the letter can be downloaded here. The Fund outperformed its small-cap benchmarks during the third quar
WILMINGTON, Mass., October 27, 2026--Charles River announces that its VCG database and methodology, designed to reduce animal use, will be used in an upcoming GLP study for Ipsen.
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. -0.9% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on CRL today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for CRL. Explore sector supply chains on /butterfly.
Why CRL Stock advanced +0.57% Today — RQD Quant Desk Flash. Solid 41% profit margin (0% return on capital), mixed timing at current multiples—hold if owned, no rush to chase.